This is supported by evidence from randomised controlled trials which have reported benefits of inhaled nebulised IFN-β as a treatment of virus-induced worsening of asthma in difficult-to-treat asthma61, and of patients admitted to hospital with severe COVID-1962. This evidence concerns the gene IFNB1 and asthma.